Revolution Medicines is forging ahead with plans to develop its multi-RAS inhibitor, RMC-6236, to tackle pancreatic cancer, but investor concerns about the drug’s safety in lung cancer have caused its share price to dip.
Revolution’s RAS Plans Move Ahead Despite Investors’ Safety Doubts
Tolerability problems with a high dose of its multi-RAS inhibitor in NSCLC patients knocked shares, but Revolution is pressing on in this setting and in pancreatic cancer. It also has eye-catching early results in colorectal cancer.
More from Clinical Trials
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
More from Scrip
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.